Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: efgartigimod Clear all
Completed Phase 2Phase 3 Interventional Results available

A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

NCT05267600
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
efgartigimod PH20 SC, placebo, Prednisone
Biological · Other · Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Fountain Valley, California • Redwood City, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 17, 2026, 2:16 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis

NCT04818671
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Carlsbad, California • Palo Alto, California • Boca Raton, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 17, 2026, 2:16 AM EDT
Completed Phase 2Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

NCT05523167
View directory record Official record
Conditions
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Interventions
EFG PH20 SC, PBO
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 3 Interventional

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

NCT06307613
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Beverly Hills, California • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 17, 2026, 2:16 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

NCT07673744
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Ublituximab, Placebo
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Colorado Springs, Colorado • Clearwater, Florida • Farmington Hills, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 17, 2026, 2:16 AM EDT
Recruiting No phase listed Observational

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

NCT07294170
View directory record Official record
Conditions
Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG), AChR-Ab Seropositive Generalized Myasthenia Gravis
Interventions
Efgartigimod IV, Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Carlsbad, California • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 3 Interventional

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.

NCT06307626
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Mission Hills, California • Rancho Cordova, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 17, 2026, 2:16 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

NCT04687072
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
14
States / cities
Springdale, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 17, 2026, 2:16 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis

NCT04735432
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
efgartigimod PH20 SC, efgartigimod IV
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
14
States / cities
Carlsbad, California • Orange, California • Boca Raton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 17, 2026, 2:16 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS

NCT05633407
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome
Interventions
Efgartigimod, Placebo
Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
La Jolla, California • Palo Alto, California • Glenview, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 17, 2026, 2:16 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

NCT03669588
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
ARGX-113, Placebo
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
25
States / cities
Phoenix, Arizona • Carlsbad, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 17, 2026, 2:16 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

NCT04281472
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Interventions
efgartigimod PH20 SC in stage B, placebo in stage B
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 17, 2026, 2:16 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Efgartigimod in Patients With IgG4-Related Disease

NCT07025330
View directory record Official record
Conditions
IgG4-related Disease
Interventions
Efgartigimod
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 17, 2026, 2:16 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

NCT06392386
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
2 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Charlotte, North Carolina • Denton, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 2:16 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

NCT07570316
View directory record Official record
Conditions
Graves' Disease, Graves Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
27
States / cities
Orange, California • Pasadena, California • San Jose, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 2:16 AM EDT
Not yet recruiting Phase 2 Interventional

A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults

NCT07583641
View directory record Official record
Conditions
Autoimmune Encephalitis (AE)
Interventions
Efgartigimod PH20 (ARGX-113) SC, Placebo PH20 SC
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
12 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Tucson, Arizona • Sherman, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 17, 2026, 2:16 AM EDT
Completed Phase 3 Interventional

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

NCT04225156
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
efgartigimod
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Ocala, Florida • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 17, 2026, 2:16 AM EDT
Withdrawn Phase 2 Interventional

Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome

NCT05701189
View directory record Official record
Conditions
Guillain-Barre Syndrome
Interventions
Efgartigimod Alfa-Fcab, Intravenous Immunoglobulin (IVIg)
Drug
Lead sponsor
Chafic Karam
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 17, 2026, 2:16 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

NCT04598477
View directory record Official record
Conditions
Pemphigus Vulgaris, Pemphigus Foliaceus
Interventions
efgartigimod PH20 SC, prednisone
Biological · Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 17, 2026, 2:16 AM EDT
Recruiting Phase 4 Interventional

Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod

NCT06860633
View directory record Official record
Conditions
Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, AChR Myasthenia Gravis
Interventions
Efgartigimod
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 17, 2026, 2:16 AM EDT
Recruiting No phase listed Observational

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

NCT06299748
View directory record Official record
Conditions
Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Efgartigimod
Biological
Lead sponsor
argenx
Industry
Eligibility
Female only
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 17, 2026, 2:16 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

NCT04188379
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
efgartigimod, Placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Tucson, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 17, 2026, 2:16 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

NCT06558279
View directory record Official record
Conditions
Myasthenia Gravis, Ocular
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
20
States / cities
Scottsdale, Arizona • Loma Linda, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 17, 2026, 2:16 AM EDT
Not yet recruiting Phase 2 Interventional

Efgartigimod for Stiff Person Syndrome (ESPS)

NCT06528392
View directory record Official record
Conditions
Stiff-Person Syndrome
Interventions
Efgartigimod
Biological
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 17, 2026, 2:16 AM EDT